{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:02:51Z","timestamp":1792958571149,"version":"4.5.0"},"reference-count":93,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,12,16]]},"abstract":"<jats:sec id=\"ab-jrv250025-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Melanoma, the fifth most common cancer in the US, has increased from 8.8 per 100\u202f000 in 1975 to 28.42 per 100\u202f000 in 2022. Cutaneous melanoma comprises 94% of cases, with 104\u202f960 US cases projected for 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250025-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Cutaneous melanoma presents as a new, changing, or irregularly pigmented skin lesion. Cutaneous melanoma subtypes include superficial spreading (\u224870%), lentigo maligna (\u224815%), nodular (\u22485%), desmoplastic (\u22484%), amelanotic (2%-8%), spitzoid (&amp;amp;lt;2%), and acral (\u22481%). Risk factors for cutaneous melanoma include UV radiation exposure, skin type (eg, skin that always burns, never tans), presence of benign and atypical nevi, and personal or family history of melanoma. Primary prevention consists of avoiding direct sunlight and indoor tanning, and photoprotection (sunscreen and sun-protective clothing). Based on United States Cancer Statistics data from 1999 to 2021, 77% of patients with cutaneous melanoma had localized disease (involving only the primary site), 9.5% had regional (nodal) disease, 4.7% had distant metastasis, and 8.8% were unstaged. Melanoma staging, which includes tumor thickness and ulceration and presence of lymph node or distant metastasis, ranges from stage 0 (melanoma in situ) to stage IV (distant metastasis). Localized melanoma (stage IA-IIA) is surgically excised, with margins of 0.5 cm to 2 cm based on depth of invasion. Sentinel lymph node biopsy is recommended for cutaneous melanoma that is ulcerated or 0.8 mm or more thick. Following surgery, patients with stage IIB-C melanoma have improved recurrence-free survival with adjuvant anti\u2013PD-1 immunotherapy compared with placebo (hazard ratio [HR] for recurrence or death, 0.62 [95% CI, 0.49-0.79] for pembrolizumab and 0.42 [95% CI, 0.30-0.59] for nivolumab). For stage III disease, recurrence risk is decreased with nivolumab (HR, 0.72 [95% CI, 0.60-0.86]), pembrolizumab (HR, 0.61 [95% CI, 0.51-0.72]), or BRAF\u2009+\u2009MEK inhibitor therapy (dabrafenib\u2009+\u2009trametinib) (HR, 0.52 [95% CI, 0.43-0.63]). First-line treatment for distant metastatic or unresectable melanoma is dual checkpoint blockade with ipilimumab (anti\u2013CTLA-4) and nivolumab. In 2017, 10-year melanoma-specific survival rates were 98% to 94% for stage IA-B, 88% to 75% for stage IIA-C, 88% for stage IIIA, 77% to 60% for stage IIIB-C, and 24% for stage IIID. In 2024, patients with distant metastatic or unresectable melanoma treated with ipilimumab and nivolumab had a 10-year overall survival rate of 43%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250025-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Melanoma is a common cancer in the US. Treatment for stage IA-IIA melanoma is surgical resection. Anti\u2013PD-1 immunotherapy after surgical excision improves recurrence-free survival in stages IIB-C melanoma. For stage III melanoma, anti\u2013PD-1 immunotherapy or BRAF\u2009+\u2009MEK inhibitor therapy decreases risk of melanoma recurrence. First-line therapy for metastatic melanoma is dual checkpoint blockade with ipilimumab and nivolumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.13074","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T15:31:00Z","timestamp":1756135860000},"page":"2113","source":"Crossref","is-referenced-by-count":67,"title":["Cutaneous Melanoma"],"prefix":"10.1001","volume":"334","author":[{"given":"Urvashi Mitbander","family":"Joshi","sequence":"first","affiliation":[{"name":"University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania"},{"name":"Now with Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Kashani-Sabet","sequence":"additional","affiliation":[{"name":"Center for Melanoma Research and Treatment, California Pacific Medical Center (CPMC) and CPMC Research Institute, Sutter Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"jrv250025r1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040.","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"1","key":"jrv250025r3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"jrv250025r4","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000000272","article-title":"An assessment of histological margins and recurrence of melanoma in situ.","volume":"3","author":"Joyce","year":"2015","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"10","key":"jrv250025r5","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/jnci\/djac138","article-title":"Incidence of in situ vs invasive melanoma: testing the \u201cobligate precursor\u201d hypothesis.","volume":"114","author":"Olsen","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"jrv250025r6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2105\/AJPH.2020.305567","article-title":"New systematic therapies and trends in cutaneous melanoma deaths among US whites, 1986-2016.","volume":"110","author":"Berk-Krauss","year":"2020","journal-title":"Am J Public Health"},{"issue":"2","key":"jrv250025r7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/CM9.0000000000003416","article-title":"Recent global patterns in skin cancer incidence, mortality, and prevalence.","volume":"138","author":"Wang","year":"2025","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"jrv250025r8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"jrv250025r9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jamadermatol.2019.3353","article-title":"Age-specific incidence of melanoma in the United States.","volume":"156","author":"Paulson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10","key":"jrv250025r10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70697","article-title":"Trends in melanoma incidence, prevalence, stage at diagnosis, and survival: an analysis of the United States Cancer Statistics (USCS) database.","volume":"16","author":"Okobi","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"jrv250025r11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jaad.2022.04.057","article-title":"Melanoma in skin of color, part II: racial disparities, role of UV, and interventions for earlier detection.","volume":"89","author":"Brunsgaard","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"jrv250025r12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.aopr.2024.10.001","article-title":"Global incidence and prevalence in uveal melanoma.","volume":"4","author":"Hou","year":"2024","journal-title":"Adv Ophthalmol Pract Res"},{"issue":"4","key":"jrv250025r13","doi-asserted-by":"publisher","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway.","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"jrv250025r14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease.","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"jrv250025r15","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s11912-023-01453-x","article-title":"Mucosal melanoma: epidemiology, clinical features, and treatment.","volume":"25","author":"Sergi","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"jrv250025r16","first-page":"739","article-title":"Primary mucosal melanomas: a comprehensive review.","volume":"5","author":"Mihajlovic","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"issue":"9","key":"jrv250025r17","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3390\/cancers12092362","article-title":"Uncommon subtypes of malignant melanomas: a review based on clinical and molecular perspectives.","volume":"12","author":"Chac\u00f3n","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"jrv250025r18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/archdermatol.2010.2","article-title":"Increased risk of second primary cancers after a diagnosis of melanoma.","volume":"146","author":"Bradford","year":"2010","journal-title":"Arch Dermatol"},{"issue":"14","key":"jrv250025r19","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.ejca.2005.03.034","article-title":"Meta-analysis of risk factors for cutaneous melanoma, III: family history, actinic damage and phenotypic factors.","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"issue":"1","key":"jrv250025r20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2004.10.015","article-title":"Meta-analysis of risk factors for cutaneous melanoma, I: common and atypical naevi.","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"issue":"1","key":"jrv250025r21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-analysis of risk factors for cutaneous melanoma, II: sun exposure.","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"jrv250025r22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4757","article-title":"Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis.","volume":"345","author":"Boniol","year":"2012","journal-title":"BMJ"},{"issue":"9","key":"jrv250025r23","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1002\/cncr.21404","article-title":"Increased incidence of melanoma in renal transplantation recipients.","volume":"104","author":"Hollenbeak","year":"2005","journal-title":"Cancer"},{"key":"jrv250025r24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2047-1440-3-10","article-title":"Systematic review of melanoma incidence and prognosis in solid organ transplant recipients.","volume":"3","author":"Dahlke","year":"2014","journal-title":"Transplant Res"},{"issue":"5","key":"jrv250025r25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.clindermatol.2019.07.010","article-title":"Skin typing: Fitzpatrick grading and others.","volume":"37","author":"Gupta","year":"2019","journal-title":"Clin Dermatol"},{"issue":"2","key":"jrv250025r26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/jamadermatol.2020.4616","article-title":"UV exposure and the risk of cutaneous melanoma in skin of color: a systematic review.","volume":"157","author":"Lopes","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"jrv250025r27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/exd.13805","article-title":"Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.","volume":"28","author":"Yan","year":"2019","journal-title":"Exp Dermatol"},{"issue":"12","key":"jrv250025r28","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/archderm.139.12.1620","article-title":"Cutaneous melanomas associated with nevi.","volume":"139","author":"Bevona","year":"2003","journal-title":"Arch Dermatol"},{"issue":"3","key":"jrv250025r29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/archderm.139.3.282","article-title":"The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate.","volume":"139","author":"Tsao","year":"2003","journal-title":"Arch Dermatol"},{"issue":"11","key":"jrv250025r30","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/archderm.137.11.1493","article-title":"Genetic epidemiology of cutaneous melanoma: a global perspective.","volume":"137","author":"Goldstein","year":"2001","journal-title":"Arch Dermatol"},{"issue":"20","key":"jrv250025r31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/jnci\/dji312","article-title":"Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.","volume":"97","author":"Begg","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"jrv250025r32","doi-asserted-by":"publisher","first-page":"9818","DOI":"10.1158\/0008-5472.CAN-06-0494","article-title":"High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.","volume":"66","author":"Goldstein","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"jrv250025r33","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3892\/ijo.2018.4287","article-title":"Cutaneous melanoma: from pathogenesis to therapy.","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int J Oncol"},{"issue":"7","key":"jrv250025r34","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.3390\/cimb45070352","article-title":"Pathology and molecular biology of melanoma.","volume":"45","author":"Timis","year":"2023","journal-title":"Curr Issues Mol Biol"},{"issue":"15","key":"jrv250025r35","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1001\/jama.2023.4342","article-title":"Screening for skin cancer: US Preventive Services Task Force recommendation statement.","volume":"329","author":"US Preventive Services Task Force","year":"2023","journal-title":"JAMA"},{"issue":"15","key":"jrv250025r36","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1001\/jama.2023.3262","article-title":"Skin cancer screening: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"329","author":"Henrikson","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"jrv250025r37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/bmjebm-2023-112460","article-title":"Ecological study estimating melanoma overdiagnosis in the USA using the lifetime risk method.","volume":"29","author":"Adamson","year":"2024","journal-title":"BMJ Evid Based Med"},{"issue":"4","key":"jrv250025r38","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamadermatol.2022.0139","article-title":"Estimating overdiagnosis of melanoma using trends among Black and White patients in the US.","volume":"158","author":"Adamson","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"5","key":"jrv250025r39","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1001\/jamadermatol.2022.0253","article-title":"Five-Year outcomes of a melanoma screening initiative in a large health care system.","volume":"158","author":"Matsumoto","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"jrv250025r40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bjd.21649","article-title":"The effect of screening on melanoma incidence and biopsy rates.","volume":"187","author":"Whiteman","year":"2022","journal-title":"Br J Dermatol"},{"issue":"12","key":"jrv250025r41","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/jamadermatol.2021.3884","article-title":"Association between melanoma detected during routine skin checks and mortality.","volume":"157","author":"Watts","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"4","key":"jrv250025r42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/archderm.141.4.434","article-title":"First prospective study of the recognition process of melanoma in dermatological practice.","volume":"141","author":"Gachon","year":"2005","journal-title":"Arch Dermatol"},{"issue":"8","key":"jrv250025r43","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5694\/mja17.00123","article-title":"Clinical practice guidelines for the diagnosis and management of melanoma: melanomas that lack classical clinical features.","volume":"207","author":"Mar","year":"2017","journal-title":"Med J Aust"},{"key":"jrv250025r44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.627527","article-title":"Melanoma of unknown primary: evaluation of the characteristics, treatment strategies, prognostic factors in a monocentric retrospective study.","volume":"11","author":"Del Fiore","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"jrv250025r45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011902.pub2","article-title":"Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults.","volume":"12","author":"Dinnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"jrv250025r46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jss.2022.12.042","article-title":"Clinical impact and accuracy of shave biopsy for initial diagnosis of cutaneous melanoma.","volume":"286","author":"Jones","year":"2023","journal-title":"J Surg Res"},{"issue":"1","key":"jrv250025r47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50613","article-title":"Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis classification schema for melanocytic lesions: a consensus statement.","volume":"6","author":"Barnhill","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"21","key":"jrv250025r48","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1002\/cncr.33088","article-title":"Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system.","volume":"126","author":"Kashani-Sabet","year":"2020","journal-title":"Cancer"},{"issue":"4","key":"jrv250025r51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/JCO.2017.75.7724","article-title":"Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update.","volume":"36","author":"Wong","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"jrv250025r52","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma.","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv250025r53","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamadermatol.2023.0127","article-title":"Early detection and prognostic assessment of cutaneous melanoma: consensus on optimal practice and the role of gene expression profile testing.","volume":"159","author":"Kashani-Sabet","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"9","key":"jrv250025r54","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2020.1731","article-title":"Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis.","volume":"156","author":"Marchetti","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"jrv250025r55","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/cancers16050895","article-title":"A review of contemporary guidelines and evidence for wide local excision in primary cutaneous melanoma management.","volume":"16","author":"Orme","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"jrv250025r56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5694\/mja17.00278","article-title":"Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma.","volume":"208","author":"Sladden","year":"2018","journal-title":"Med J Aust"},{"issue":"2","key":"jrv250025r57","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"issue":"23","key":"jrv250025r58","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","article-title":"Molecular pathways and mechanisms of LAG-3 in cancer therapy.","volume":"28","author":"Andrews","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"jrv250025r59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"issue":"18","key":"jrv250025r60","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma.","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv250025r61","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.annonc.2024.05.002","article-title":"Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.","volume":"35","author":"Menzies","year":"2024","journal-title":"Ann Oncol"},{"issue":"7934","key":"jrv250025r62","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma.","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"14","key":"jrv250025r63","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study.","volume":"42","author":"Luke","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"jrv250025r64","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"issue":"18","key":"jrv250025r65","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant dabrafenib plus trametinib in stage III melanoma.","volume":"391","author":"Long","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv250025r66","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma.","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evidence"},{"issue":"17","key":"jrv250025r67","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238.","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"jrv250025r68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma.","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur J Cancer"},{"issue":"7","key":"jrv250025r69","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma.","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"jrv250025r70","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study.","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"jrv250025r71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma.","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"13","key":"jrv250025r72","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047.","volume":"43","author":"Tawbi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"jrv250025r73","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.","volume":"35","author":"Long","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"jrv250025r74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"23","key":"jrv250025r75","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma.","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv250025r76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"30","key":"jrv250025r77","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic therapy for melanoma: ASCO guideline update.","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"jrv250025r78","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma.","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv250025r79","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis.","volume":"7","author":"Xing","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"12","key":"jrv250025r80","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45596","article-title":"Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or combination immunotherapy.","volume":"5","author":"Watson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"jrv250025r81","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders.","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"jrv250025r82","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial\u2013ECOG-ACRIN EA6134.","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv250025r83","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial.","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"jrv250025r84","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JOP.19.00585","article-title":"American Society of Clinical Oncology policy statement on skin cancer prevention.","volume":"16","author":"Alberg","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"50","key":"jrv250025r86","doi-asserted-by":"crossref","first-page":"E1802","DOI":"10.1503\/cmaj.201085","article-title":"The efficacy and safety of sunscreen use for the prevention of skin cancer.","volume":"192","author":"Sander","year":"2020","journal-title":"CMAJ"},{"issue":"3","key":"jrv250025r87","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.2010.28.7078","article-title":"Reduced melanoma after regular sunscreen use: randomized trial follow-up.","volume":"29","author":"Green","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv250025r88","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/1097-0142(20000715)89:2<342::AID-CNCR19>3.0.CO;2-P","article-title":"Patterns of detection in patients with cutaneous melanoma.","volume":"89","author":"Brady","year":"2000","journal-title":"Cancer"},{"issue":"7","key":"jrv250025r89","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2023.1494","article-title":"Risk of mortality after a diagnosis of melanoma in situ.","volume":"159","author":"Patel","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"17","key":"jrv250025r90","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1001\/archinte.166.17.1907","article-title":"Ethnic differences among patients with cutaneous melanoma.","volume":"166","author":"Cormier","year":"2006","journal-title":"Arch Intern Med"},{"issue":"16","key":"jrv250025r91","doi-asserted-by":"crossref","first-page":"9582","DOI":"10.1200\/JCO.2023.41.16_suppl.9582","article-title":"Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II\/III melanoma.","volume":"41","author":"Kollipara","year":"2023","journal-title":"JCO"},{"issue":"11","key":"jrv250025r92","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.34716","article-title":"Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.","volume":"129","author":"Eroglu","year":"2023","journal-title":"Cancer"},{"key":"jrv250025r49","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","edition":"8th ed"},{"key":"jrv250025r93","doi-asserted-by":"crossref","article-title":"DETECTION phase II\/III trial: circulating tumor DNA\u2013guided therapy for stage IIB\/C melanoma after surgical resection.","author":"Lee","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9603"},{"key":"jrv250025r2","unstructured":"Cancer Stat Facts: Melanoma of the Skin. Surveillance, Epidemiology, and End Results Program. Accessed January 3, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html"},{"key":"jrv250025r50","unstructured":"National Comprehensive Cancer Network (NCCN) Guidelines. Melanoma: Cutaneous. Version 1. 2025. NCCN. Accessed January 19, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"key":"jrv250025r85","unstructured":"American Academy of Dermatology. Sunscreen FAQS. Accessed July 14, 2024. https:\/\/www.aad.org\/media\/stats-sunscreen"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2838001\/jama_joshi_2025_rv_250025_1765403077.86605.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:00:33Z","timestamp":1765900833000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2838001"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":93,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,16]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.13074","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}